Wockhardt Limited submitted a press release regarding the clinical efficacy of Zaynich in treating serious infections caused by resistant pathogens. The study showed that Zaynich achieved high efficacy rates in various severe infections, including bloodstream infections and pneumonia. This filing highlights the potential of Zaynich as a life-saving antibiotic amid rising antimicrobial resistance concerns.
Wockhardt Limited has informed the Exchange regarding a press release dated January 13, 2025, titled Zaynich? (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem-Resistant Gram-Negative Pathogens .".